<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<title>Bayesian Assurance of Consecutive Studies ‚Ä¢ CyneRgy</title>
<!-- favicons --><link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
<link rel="apple-touch-icon" type="image/png" sizes="180x180" href="../apple-touch-icon.png">
<link rel="apple-touch-icon" type="image/png" sizes="120x120" href="../apple-touch-icon-120x120.png">
<link rel="apple-touch-icon" type="image/png" sizes="76x76" href="../apple-touch-icon-76x76.png">
<link rel="apple-touch-icon" type="image/png" sizes="60x60" href="../apple-touch-icon-60x60.png">
<script src="../lightswitch.js"></script><script src="../deps/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<link href="../deps/bootstrap-5.3.1/bootstrap.min.css" rel="stylesheet">
<script src="../deps/bootstrap-5.3.1/bootstrap.bundle.min.js"></script><link href="../deps/font-awesome-6.4.2/css/all.min.css" rel="stylesheet">
<link href="../deps/font-awesome-6.4.2/css/v4-shims.min.css" rel="stylesheet">
<script src="../deps/headroom-0.11.0/headroom.min.js"></script><script src="../deps/headroom-0.11.0/jQuery.headroom.min.js"></script><script src="../deps/bootstrap-toc-1.0.1/bootstrap-toc.min.js"></script><script src="../deps/clipboard.js-2.0.11/clipboard.min.js"></script><script src="../deps/search-1.0.0/autocomplete.jquery.min.js"></script><script src="../deps/search-1.0.0/fuse.min.js"></script><script src="../deps/search-1.0.0/mark.min.js"></script><!-- pkgdown --><script src="../pkgdown.js"></script><meta property="og:title" content="Bayesian Assurance of Consecutive Studies">
</head>
<body>
    <a href="#main" class="visually-hidden-focusable">Skip to contents</a>


    <nav class="navbar navbar-expand-lg fixed-top " aria-label="Site navigation"><div class="container">

    <a class="navbar-brand me-2" href="../index.html">CyneRgy</a>

    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.1.3</small>


    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>

    <div id="navbar" class="collapse navbar-collapse ms-3">
      <ul class="navbar-nav me-auto">
<li class="nav-item"><a class="nav-link" href="../index.html">Home</a></li>
<li class="nav-item dropdown">
  <button class="nav-link dropdown-toggle" type="button" id="dropdown-getting-started" data-bs-toggle="dropdown" aria-expanded="false" aria-haspopup="true">Getting Started</button>
  <ul class="dropdown-menu" aria-labelledby="dropdown-getting-started">
<li><a class="dropdown-item" href="../articles/Overview.html">Overview</a></li>
    <li><hr class="dropdown-divider"></li>
    <li><h6 class="dropdown-header" data-toc-skip>Integration Specific Points</h6></li>
    <li><a class="dropdown-item" href="../articles/IntegrationPointInitialization.html">Initialization</a></li>
    <li><a class="dropdown-item" href="../articles/IntegrationPointAnalysis.html">Analysis (Test Statistic)</a></li>
    <li><a class="dropdown-item" href="../articles/IntegrationPointEnrollment.html">Enrollment (Arrival Times)</a></li>
    <li><a class="dropdown-item" href="../articles/IntegrationPointRandomization.html">Randomization (Assignment of Subjects)</a></li>
    <li><a class="dropdown-item" href="../articles/IntegrationPointResponse.html">Response (Patient Simulation)</a></li>
    <li><a class="dropdown-item" href="../articles/IntegrationPointDropout.html">Dropout</a></li>
    <li><a class="dropdown-item" href="../articles/IntegrationPointTreatmentSelection.html">Treatment Selection</a></li>
  </ul>
</li>
<li class="active nav-item dropdown">
  <button class="nav-link dropdown-toggle" type="button" id="dropdown-examples" data-bs-toggle="dropdown" aria-expanded="false" aria-haspopup="true">Examples</button>
  <ul class="dropdown-menu" aria-labelledby="dropdown-examples">
<li><a class="dropdown-item" href="../articles/ExampleOutline.html">Examples Outline</a></li>
    <li><hr class="dropdown-divider"></li>
    <li><h6 class="dropdown-header" data-toc-skip>Patient Simulation</h6></li>
    <li><a class="dropdown-item" href="../articles/2ArmNormalOutcomePatientSimulationDescription.html">2-Arm, Normal Outcome</a></li>
    <li><a class="dropdown-item" href="../articles/2ArmTimeToEventOutcomePatientSimulationDescription.html">2-Arm, Time-to-Event Outcome</a></li>
    <li><a class="dropdown-item" href="../articles/2ArmBinaryOutcomePatientSimulation.html">2-Arm, Binary Outcome</a></li>
    <li><a class="dropdown-item" href="../articles/2ArmNormalRepeatedMeasuresResponseGeneration.html">2-Arm, Repeated Measure</a></li>
    <li><a class="dropdown-item" href="../articles/ChildhoodAnxiety.html">Childhood Anxiety Trial</a></li>
    <li><hr class="dropdown-divider"></li>
    <li><h6 class="dropdown-header" data-toc-skip>Analysis</h6></li>
    <li><a class="dropdown-item" href="../articles/2ArmNormalOutcomeAnalysisDescription.html">2-Arm, Normal Outcome</a></li>
    <li><a class="dropdown-item" href="../articles/2ArmTimeToEventOutcomeAnalysisDescription.html">2-Arm, Time-To-Event Outcome</a></li>
    <li><a class="dropdown-item" href="../articles/2ArmBinaryOutcomeAnalysisDescription.html">2-Arm, Binary Outcome</a></li>
    <li><hr class="dropdown-divider"></li>
    <li><h6 class="dropdown-header" data-toc-skip>Treatment Selection</h6></li>
    <li><a class="dropdown-item" href="../articles/TreatmentSelectionDescription.html">Binary Outcome</a></li>
    <li><hr class="dropdown-divider"></li>
    <li><h6 class="dropdown-header" data-toc-skip>Advanced Examples</h6></li>
    <li><a class="dropdown-item" href="../articles/AssuranceConsecutiveStudies.html">Bayesian Assurance of Consecutive Studies</a></li>
    <li><hr class="dropdown-divider"></li>
    <li><h6 class="dropdown-header" data-toc-skip>Other Integration Points</h6></li>
    <li><a class="dropdown-item" href="../articles/GeneratePoissonArrival.html">Poisson Arrival Times</a></li>
    <li><a class="dropdown-item" href="../articles/PatientDropout.html">Patient Dropout</a></li>
    <li><a class="dropdown-item" href="../articles/PatientRandomization.html">Patient Randomization</a></li>
  </ul>
</li>
<li class="nav-item"><a class="nav-link" href="../reference/index.html">References</a></li>
<li class="nav-item"><a class="nav-link" href="../articles/ContibutingToCyneRgy.html">Contribute</a></li>
      </ul>
<ul class="navbar-nav">
<li class="nav-item"><form class="form-inline" role="search">
 <input class="form-control" type="search" name="search-input" id="search-input" autocomplete="off" aria-label="Search site" placeholder="Search for" data-search-index="../search.json">
</form></li>
<li class="nav-item"><a class="external-link nav-link" href="https://github.com/Cytel-Inc/CyneRgy"><span class="fa fa-github fa-lg"></span></a></li>
<li class="nav-item dropdown">
  <button class="nav-link dropdown-toggle" type="button" id="dropdown-lightswitch" data-bs-toggle="dropdown" aria-expanded="false" aria-haspopup="true" aria-label="Light switch"><span class="fa fa-sun"></span></button>
  <ul class="dropdown-menu dropdown-menu-end" aria-labelledby="dropdown-lightswitch">
<li><button class="dropdown-item" data-bs-theme-value="light"><span class="fa fa-sun"></span> Light</button></li>
    <li><button class="dropdown-item" data-bs-theme-value="dark"><span class="fa fa-moon"></span> Dark</button></li>
    <li><button class="dropdown-item" data-bs-theme-value="auto"><span class="fa fa-adjust"></span> Auto</button></li>
  </ul>
</li>
      </ul>
</div>


  </div>
</nav><div class="container template-article">




<div class="row">
  <main id="main" class="col-md-9"><div class="page-header">
      <img src="../logo.png" class="logo" alt=""><h1>Bayesian Assurance of Consecutive Studies</h1>
                        <h4 data-toc-skip class="author">J. Kyle Wathen
and Laurent Spiess</h4>
            
            <h4 data-toc-skip class="date">April 17, 2025</h4>
      

      <div class="d-none name"><code>AssuranceConsecutiveStudies.Rmd</code></div>
    </div>

    
    
<div class="alert alert-primary" role="alert">
<p style="margin-bottom:0">
The following scripts are related to both the
<a href="IntegrationPointAnalysis.html" class="alert-link"><strong>Integration
Point: Analysis</strong></a> and the
<a href="IntegrationPointResponse.html" class="alert-link"><strong>Integration
Point: Response</strong></a>. Click on the links for more information
about these integration points.
</p>
</div>
<div class="section level2">
<h2 id="introduction">Introduction<a class="anchor" aria-label="anchor" href="#introduction"></a>
</h2>
<p>The intent of the following examples is to demonstrate the
computation of Bayesian assurance, or probability of success, through
the integration of R with Cytel products. The first example features a
two-arm, fixed-sample trial with normally distributed outcomes, using a
non-standard prior to compute assurance. Subsequent examples advance to
more complex scenarios, including computing assurance for a sequential
design involving a phase 2 trial with normal outcomes followed by a
phase 3 trial with time-to-event outcomes.</p>
<p>All examples involve two treatments: Standard of Care (S) and
Experimental (E). The scenarios covered are as follows:</p>
<ol style="list-style-type: decimal">
<li>Fixed sample design using a mixture of normal distributions to
compute Bayesian assurance.</li>
<li>Group sequential design, expanding on Example 1, with an interim
analysis for futility based on Bayesian predictive probability.</li>
<li>Fixed design with a time-to-event outcome, serving as both a
standalone example and a reference for the later phase 2/phase 3
scenario.</li>
<li>Two consecutive studies: phase 2 with a normal endpoint followed by
phase 3, also with a normal endpoint.</li>
<li>Two consecutive studies: phase 2 with a normal endpoint followed by
phase 3 with a time-to-event outcome.</li>
</ol>
<p>Once CyneRgy is installed, you can load this example in RStudio with
the following commands:</p>
<div class="sourceCode" id="cb1"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="fu">CyneRgy</span><span class="fu">::</span><span class="fu"><a href="../reference/RunExample.html">RunExample</a></span><span class="op">(</span> <span class="st">"AssuranceConsecutiveStudies"</span> <span class="op">)</span></span></code></pre></div>
<p>Running the command above will load the RStudio project in
RStudio.</p>
<p><strong>East Workbook</strong>: <a href="https://github.com/Cytel-Inc/CyneRgy/blob/main/inst/Examples/AssuranceConsecutiveStudies/Assurance.cywx" class="external-link">AssuranceConsecutiveStudies.cywx</a></p>
<p><strong>RStudio Project File</strong>: <a href="https://github.com/Cytel-Inc/CyneRgy/blob/main/inst/Examples/AssuranceConsecutiveStudies/Assurance.Rproj" class="external-link">AssuranceConsecutiveStudies.Rproj</a></p>
<p>In the <a href="https://github.com/Cytel-Inc/CyneRgy/tree/main/inst/Examples/AssuranceConsecutiveStudies/R" class="external-link">R
directory of this example</a> you will find the R files used in the
examples.</p>
</div>
<div class="section level2">
<h2 id="example-1---fixed-sample-design-with-a-mixture-of-normal-distributions">Example 1 - Fixed Sample Design with a Mixture of Normal
Distributions<a class="anchor" aria-label="anchor" href="#example-1---fixed-sample-design-with-a-mixture-of-normal-distributions"></a>
</h2>
<p>This example considers a fixed sample design with normally
distributed outcomes
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mi>Y</mi><annotation encoding="application/x-tex">Y</annotation></semantics></math>,
with 80 patients per treatment arm. It demonstrates how to customize the
<strong>Analysis</strong> endpoint to compute the probability of
success, and the <strong>Response (Patient Simulation)</strong> endpoint
to simulate a mixture of normal distributions.</p>
<p>By integrating an R function into the Analysis endpoint, users can
evaluate the frequentist operating characteristics of the Bayesian
design in East Horizon. Additionally, by modifying the Response
endpoint, the simulation will incorporate Bayesian assurance.
Specifically, an R function first samples from the assurance prior, then
generates the patient data. The resulting power from this simulation
reflects the Bayesian assurance, assuming the two-component prior.</p>
<p>Often, it is important to examine the posterior distributions of both
the observed and true treatment differences following a Go decision.
These posterior distributions provide valuable insights for planning
subsequent study phases and assessing potential risks. The process of
obtaining these posterior distributions is detailed in the next example,
and their application to Phase 2 and Phase 3 studies is explored in
later sections.</p>
<div class="section level3">
<h3 id="analysis-endpoint">Analysis Endpoint<a class="anchor" aria-label="anchor" href="#analysis-endpoint"></a>
</h3>
<div class="alert alert-primary" role="alert">
<p style="margin-bottom:0">
This endpoint is related to this R file:
<a href="https://github.com/Cytel-Inc/CyneRgy/blob/main/inst/Examples/AssuranceConsecutiveStudies/R/AnalyzeUsingBayesianNormals.R" class="external-link alert-link">AnalyzeUsingBayesianNormals.R</a>
</p>
</div>
<p>This function evaluates the posterior probability that the
experimental treatment arm is better than the control arm by more than a
clinically meaningful threshold, and returns a Go/No-Go decision based
on a cutoff
(<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><msub><mi>P</mi><mi>U</mi></msub><annotation encoding="application/x-tex">P_U</annotation></semantics></math>).</p>
<p>For patients receiving treatment
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>j</mi><mo>‚àà</mo><mo stretchy="false" form="prefix">{</mo><mtext mathvariant="normal">S</mtext><mo>,</mo><mtext mathvariant="normal">E</mtext><mo stretchy="false" form="postfix">}</mo></mrow><annotation encoding="application/x-tex">j \in \{\text{S}, \text{E}\}</annotation></semantics></math>
(S = standard/control, E = experimental), we assume the outcomes
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>Y</mi><mo>‚àº</mo><mi>ùí©</mi><mrow><mo stretchy="true" form="prefix">(</mo><msub><mi>Œº</mi><mi>j</mi></msub><mo>,</mo><msup><mi>œÉ</mi><mn>2</mn></msup><mo stretchy="true" form="postfix">)</mo></mrow></mrow><annotation encoding="application/x-tex">Y \sim \mathcal{N}(\mu_j, \sigma^2)</annotation></semantics></math>,
where
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><msub><mi>Œº</mi><mi>j</mi></msub><annotation encoding="application/x-tex">\mu_j</annotation></semantics></math>
is an unknown mean and
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><msup><mi>œÉ</mi><mn>2</mn></msup><annotation encoding="application/x-tex">\sigma^2</annotation></semantics></math>
is a known, fixed variance.</p>
<p>We assume <em>a priori</em> that:</p>
<p><math display="block" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>Œº</mi><mi>j</mi></msub><mo>‚àº</mo><mi>ùí©</mi><mrow><mo stretchy="true" form="prefix">(</mo><msub><mi>Œ∏</mi><mi>j</mi></msub><mo>,</mo><msubsup><mi>œÑ</mi><mi>j</mi><mn>2</mn></msubsup><mo>=</mo><msup><mn>1000</mn><mn>2</mn></msup><mo stretchy="true" form="postfix">)</mo></mrow><mo>,</mo><mspace width="1.0em"></mspace><mi>j</mi><mo>‚àà</mo><mo stretchy="false" form="prefix">{</mo><mtext mathvariant="normal">S</mtext><mo>,</mo><mtext mathvariant="normal">E</mtext><mo stretchy="false" form="postfix">}</mo></mrow><annotation encoding="application/x-tex">
\mu_j \sim \mathcal{N}(\theta_j, \tau_j^2 = 1000^2), \quad j \in \{\text{S}, \text{E}\}
</annotation></semantics></math></p>
<p>After observing
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mi>n</mi><annotation encoding="application/x-tex">n</annotation></semantics></math>
patients on treatment
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mi>j</mi><annotation encoding="application/x-tex">j</annotation></semantics></math>,
the posterior distribution of
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><msub><mi>Œº</mi><mi>j</mi></msub><annotation encoding="application/x-tex">\mu_j</annotation></semantics></math>
becomes:</p>
<p><math display="block" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>Œº</mi><mi>j</mi></msub><mo>‚à£</mo><mover><mi>y</mi><mo accent="true">‚Äæ</mo></mover><mo>‚àº</mo><mi>ùí©</mi><mrow><mo stretchy="true" form="prefix">(</mo><msubsup><mi>Œ∏</mi><mi>j</mi><mo>*</mo></msubsup><mo>,</mo><msubsup><mi>œÑ</mi><mi>j</mi><mrow><mn>2</mn><mo>*</mo></mrow></msubsup><mo stretchy="true" form="postfix">)</mo></mrow></mrow><annotation encoding="application/x-tex">
\mu_j \mid \bar{y} \sim \mathcal{N}(\theta_j^*, \tau_j^{2*})
</annotation></semantics></math> where:</p>
<p><math display="block" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msubsup><mi>Œ∏</mi><mi>j</mi><mo>*</mo></msubsup><mo>=</mo><mfrac><mrow><mfrac><msub><mi>Œ∏</mi><mi>j</mi></msub><msubsup><mi>œÑ</mi><mi>j</mi><mn>2</mn></msubsup></mfrac><mo>+</mo><mfrac><mrow><mi>n</mi><mover><mi>y</mi><mo accent="true">‚Äæ</mo></mover></mrow><msup><mi>œÉ</mi><mn>2</mn></msup></mfrac></mrow><mrow><mfrac><mn>1</mn><msubsup><mi>œÑ</mi><mi>j</mi><mn>2</mn></msubsup></mfrac><mo>+</mo><mfrac><mi>n</mi><msup><mi>œÉ</mi><mn>2</mn></msup></mfrac></mrow></mfrac><mo>,</mo><mspace width="1.0em"></mspace><mtext mathvariant="normal">and</mtext><mspace width="1.0em"></mspace><mfrac><mn>1</mn><msubsup><mi>œÑ</mi><mi>j</mi><mrow><mn>2</mn><mo>*</mo></mrow></msubsup></mfrac><mo>=</mo><mfrac><mn>1</mn><msubsup><mi>œÑ</mi><mi>j</mi><mn>2</mn></msubsup></mfrac><mo>+</mo><mfrac><mi>n</mi><msup><mi>œÉ</mi><mn>2</mn></msup></mfrac></mrow><annotation encoding="application/x-tex">
\theta_j^* = \frac{\frac{\theta_j}{\tau_j^2} + \frac{n \bar{y}}{\sigma^2}}{\frac{1}{\tau_j^2} + \frac{n}{\sigma^2}}, \quad \text{and} \quad
\frac{1}{\tau_j^{2*}} = \frac{1}{\tau_j^2} + \frac{n}{\sigma^2}
</annotation></semantics></math></p>
<p>At the conclusion of the study, the posterior probability that the
experimental arm exceeds the control arm by more than the minimum
acceptable value (MAV) is calculated as:</p>
<p><math display="block" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>œÅ</mi><mo>=</mo><mo>Pr</mo><mrow><mo stretchy="true" form="prefix">(</mo><msub><mi>Œº</mi><mi>E</mi></msub><mo>&gt;</mo><msub><mi>Œº</mi><mi>S</mi></msub><mo>+</mo><mtext mathvariant="normal">MAV</mtext><mo>‚à£</mo><mtext mathvariant="normal">data</mtext><mo stretchy="true" form="postfix">)</mo></mrow></mrow><annotation encoding="application/x-tex">
\rho = \Pr(\mu_E &gt; \mu_S + \text{MAV} \mid \text{data})
</annotation></semantics></math></p>
<p>The decision rule is as follows:</p>
<ul>
<li>If
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>œÅ</mi><mo>&gt;</mo><msub><mi>P</mi><mi>U</mi></msub><mo>‚Üí</mo></mrow><annotation encoding="application/x-tex">\rho &gt; P_U \rightarrow</annotation></semantics></math>
Go.</li>
<li>If
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>œÅ</mi><mo>‚â§</mo><msub><mi>P</mi><mi>U</mi></msub><mo>‚Üí</mo></mrow><annotation encoding="application/x-tex">\rho \leq P_U \rightarrow</annotation></semantics></math>
No-Go.</li>
</ul>
<p>Refer to the table below for the definitions and values of the
user-defined parameters used in this example.</p>
<table class="table">
<colgroup>
<col width="27%">
<col width="54%">
<col width="18%">
</colgroup>
<thead><tr class="header">
<th><strong>User parameter</strong></th>
<th><strong>Definition</strong></th>
<th><strong>Value</strong></th>
</tr></thead>
<tbody>
<tr class="odd">
<td><strong>dPriorMeanCtrl</strong></td>
<td>Prior mean for control arm.</td>
<td>0</td>
</tr>
<tr class="even">
<td><strong>dPriorStdDevCtrl</strong></td>
<td>Prior standard deviation for control arm.</td>
<td>1000</td>
</tr>
<tr class="odd">
<td><strong>dPriorMeanExp</strong></td>
<td>Prior mean for experimental arm.</td>
<td>0</td>
</tr>
<tr class="even">
<td><strong>dPriorStdDevExp</strong></td>
<td>Prior standard deviation for experimental arm.</td>
<td>1000</td>
</tr>
<tr class="odd">
<td><strong>dSigma</strong></td>
<td>Known sampling standard deviation.</td>
<td>1.9</td>
</tr>
<tr class="even">
<td><strong>dMAV</strong></td>
<td>Minimum Acceptable Value (clinically meaningful difference).</td>
<td>0.8</td>
</tr>
<tr class="odd">
<td><strong>dPU</strong></td>
<td>Go threshold (posterior probability cutoff).</td>
<td>0.8</td>
</tr>
</tbody>
</table>
</div>
<div class="section level3">
<h3 id="response-patient-simulation-endpoint">Response (Patient Simulation) Endpoint<a class="anchor" aria-label="anchor" href="#response-patient-simulation-endpoint"></a>
</h3>
<div class="alert alert-primary" role="alert">
<p style="margin-bottom:0">
This endpoint is related to this R file:
<a href="https://github.com/Cytel-Inc/CyneRgy/blob/main/inst/Examples/AssuranceConsecutiveStudies/R/SimulatePatientOutcomeNormalAssurance.R" class="external-link alert-link">SimulatePatientOutcomeNormalAssurance.R</a>
</p>
</div>
<p>This function simulates patient-level outcomes within a Bayesian
assurance framework, using a two-component mixture prior to reflect
uncertainty about the true treatment effect. It allows for assessing the
probability of trial success (assurance) under uncertainty about the
true treatment effect.</p>
<p>In this example, the true treatment effect
(<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>Œº</mi><mi>E</mi></msub><mo>‚àí</mo><msub><mi>Œº</mi><mi>S</mi></msub></mrow><annotation encoding="application/x-tex">\mu_E - \mu_S</annotation></semantics></math>)
is sampled from a mixture of two normal priors:</p>
<ul>
<li>25% weight on
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>ùí©</mi><mrow><mo stretchy="true" form="prefix">(</mo><mn>0</mn><mo>,</mo><msup><mn>0.05</mn><mn>2</mn></msup><mo stretchy="true" form="postfix">)</mo></mrow></mrow><annotation encoding="application/x-tex">\mathcal{N}(0, 0.05^2)</annotation></semantics></math>.</li>
<li>75% weight on
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>ùí©</mi><mrow><mo stretchy="true" form="prefix">(</mo><mn>0.7</mn><mo>,</mo><msup><mn>0.3</mn><mn>2</mn></msup><mo stretchy="true" form="postfix">)</mo></mrow></mrow><annotation encoding="application/x-tex">\mathcal{N}(0.7, 0.3^2)</annotation></semantics></math>.</li>
</ul>
<p>The control mean is fixed, while the experimental mean is computed as
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>d</mi><mtext mathvariant="normal">MeanCtrl</mtext><mo>+</mo><mtext mathvariant="normal">treatment effect</mtext></mrow><annotation encoding="application/x-tex">d\text{MeanCtrl} + \text{treatment effect}</annotation></semantics></math>.
Each patient‚Äôs response is then simulated from a normal distribution
corresponding to their assigned treatment group, with standard
deviations defined separately for each arm.</p>
<p><img src="AssuranceConsecutiveStudies_files/figure-html/unnamed-chunk-4-1.png" width="700"></p>
<p>Refer to the table below for the definitions and values of the
user-defined parameters used in this example.</p>
<table class="table">
<colgroup>
<col width="20%">
<col width="60%">
<col width="20%">
</colgroup>
<thead><tr class="header">
<th><strong>User parameter</strong></th>
<th><strong>Definition</strong></th>
<th><strong>Value</strong></th>
</tr></thead>
<tbody>
<tr class="odd">
<td><strong>dWeight1</strong></td>
<td>Weight of prior component 1.</td>
<td>0.25</td>
</tr>
<tr class="even">
<td><strong>dWeight2</strong></td>
<td>Weight of prior component 2.</td>
<td>0.75</td>
</tr>
<tr class="odd">
<td><strong>dMean1</strong></td>
<td>Mean of prior component 1.</td>
<td>0</td>
</tr>
<tr class="even">
<td><strong>dMean2</strong></td>
<td>Mean of prior component 2.</td>
<td>0.7</td>
</tr>
<tr class="odd">
<td><strong>dSD1</strong></td>
<td>Standard deviation of prior component 1.</td>
<td>0.05</td>
</tr>
<tr class="even">
<td><strong>dSD2</strong></td>
<td>Standard deviation of prior component 2.</td>
<td>0.3</td>
</tr>
<tr class="odd">
<td><strong>dMeanCtrl</strong></td>
<td>Mean of control arm (experimental arm will be sampled).</td>
<td>0</td>
</tr>
<tr class="even">
<td><strong>dSDCtrl</strong></td>
<td>Standard deviation for control arm.</td>
<td>1.9</td>
</tr>
<tr class="odd">
<td><strong>dSDExp</strong></td>
<td>Standard deviation for experimental arm.</td>
<td>1.9</td>
</tr>
</tbody>
</table>
</div>
<div class="section level3">
<h3 id="results">Results<a class="anchor" aria-label="anchor" href="#results"></a>
</h3>
<p>The probability of a Go is 15.3% and the probability of a No-Go is
84.7%.</p>
<p><img src="AssuranceConsecutiveStudies_files/figure-html/unnamed-chunk-6-1.png" width="700"></p>
</div>
</div>
<div class="section level2">
<h2 id="example-2">Example 2<a class="anchor" aria-label="anchor" href="#example-2"></a>
</h2>
<div class="section level3">
<h3 id="study-design">Study Design<a class="anchor" aria-label="anchor" href="#study-design"></a>
</h3>
<p>Same study design as previous example, however, this design includes
an interim analysis to check for futility when 50% of the patients have
their outcome observed. The futility rule is based on a Bayesian
predictive probability of a No-Go at the end of the study. That is, at
the interim analysis if it is likely that the study will make a No-Go
decision at the final analysis, then the study is stopped early for
futility.</p>
<p>Denote the data at the interim analysis by
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><msub><mi>X</mi><mn>1</mn></msub><annotation encoding="application/x-tex">X_1</annotation></semantics></math>
and data for patients enrolled after the IA by
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><msub><mi>X</mi><mn>2</mn></msub><annotation encoding="application/x-tex">X_2</annotation></semantics></math>.
If the predictive probability of a No-Go at the final analysis is
greater than
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi><msub><mi>U</mi><mrow><mi>F</mi><mi>u</mi><mi>t</mi><mi>i</mi><mi>l</mi><mi>i</mi><mi>t</mi><mi>y</mi></mrow></msub><mo>=</mo><mn>90</mn></mrow><annotation encoding="application/x-tex">PU_{Futility} = 90</annotation></semantics></math>%
then the trial is stopped for futility. Specifically, if
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi><mi>r</mi><mrow><mo stretchy="true" form="prefix">(</mo><mtext mathvariant="normal">End of Study No-Go</mtext><mo stretchy="false" form="prefix">|</mo><msub><mi>X</mi><mn>1</mn></msub><mo stretchy="true" form="postfix">)</mo></mrow><mo>&gt;</mo><mi>P</mi><msub><mi>U</mi><mrow><mi>F</mi><mi>u</mi><mi>t</mi><mi>i</mi><mi>l</mi><mi>i</mi><mi>t</mi><mi>y</mi></mrow></msub><mo>=</mo><mn>90</mn><mi>%</mi></mrow><annotation encoding="application/x-tex">Pr( \text{End of Study No-Go} | X_1 ) &gt; PU_{Futility} = 90\%</annotation></semantics></math>
then the trial is stopped for futility. The prediction formula
becomes:</p>
<p><math display="block" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi><mi>r</mi><mrow><mo stretchy="true" form="prefix">(</mo><mtext mathvariant="normal">End of Study No-Go</mtext><mo stretchy="false" form="prefix">|</mo><msub><mi>X</mi><mn>1</mn></msub><mo stretchy="true" form="postfix">)</mo></mrow><mo>=</mo><mi>P</mi><mi>r</mi><mrow><mo stretchy="true" form="prefix">[</mo><mo stretchy="false" form="prefix">{</mo><mi>P</mi><mi>r</mi><mo stretchy="false" form="prefix">(</mo><msub><mi>Œº</mi><mi>E</mi></msub><mo>&gt;</mo><msub><mi>Œº</mi><mi>S</mi></msub><mo>+</mo><mi>M</mi><mi>A</mi><mi>V</mi><mrow><mo stretchy="true" form="prefix">|</mo><msub><mi>X</mi><mn>1</mn></msub><mo>,</mo><msub><mi>X</mi><mn>2</mn></msub><mo stretchy="false" form="postfix">)</mo><mo>&gt;</mo><mi>P</mi><mi>U</mi><mo stretchy="false" form="postfix">}</mo><mo stretchy="true" form="postfix">|</mo></mrow><msub><mi>X</mi><mn>1</mn></msub><mo stretchy="true" form="postfix">]</mo></mrow><mo>&gt;</mo><mi>P</mi><msub><mi>U</mi><mrow><mi>F</mi><mi>u</mi><mi>t</mi><mi>i</mi><mi>l</mi><mi>i</mi><mi>t</mi><mi>y</mi></mrow></msub></mrow><annotation encoding="application/x-tex">
Pr( \text{End of Study No-Go} | X_1 ) = Pr[ \{ Pr( \mu_E &gt; \mu_S + MAV | X_1, X_2 ) &gt; PU \} | X_1  ] &gt; PU_{Futility}
</annotation></semantics></math></p>
</div>
<div class="section level3">
<h3 id="r-integration">R Integration<a class="anchor" aria-label="anchor" href="#r-integration"></a>
</h3>
<p>In order to evaluate the design above, one can develop an R function
for analysis that can be called from East during simulation. By
replacing only the analysis function with an R function, one can obtain
the frequentist operating characteristics of the Bayesian design using
East that includes the interim analysis and futility check based on a
Bayesian predictive probability. In addition, by replacing how the
patient data is simulated one can obtain the Bayesian assurance.
Specifically, in the simulation when the patient data is simulated an R
function will first sample the assurance prior then sample the patient
data. The resulting power of this simulation will be the Bayesian
assurance assuming the 2 component prior given in Example 1 and
including the futility check.</p>
<div class="section level4">
<h4 id="required-r-functions">Required R Functions<a class="anchor" aria-label="anchor" href="#required-r-functions"></a>
</h4>
<p>Same as example 1, just need to provide the
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi><msub><mi>U</mi><mrow><mi>F</mi><mi>u</mi><mi>t</mi><mi>i</mi><mi>l</mi><mi>i</mi><mi>t</mi><mi>y</mi></mrow></msub></mrow><annotation encoding="application/x-tex">PU_{Futility}</annotation></semantics></math>
parameter. The same R code function is used for Example 1 and 2. The
only difference between this example and Example 1 is the addition of
the dPUFutility and the interim analysis.</p>
<div class="float">
<img src="Example2TestStatisticInput.jpg" alt="Input for test statistitic input"><div class="figcaption">Input for test statistitic input</div>
</div>
</div>
</div>
<div class="section level3">
<h3 id="results-1">Results<a class="anchor" aria-label="anchor" href="#results-1"></a>
</h3>
<p>The results of the design are as follows:</p>
<ul>
<li>The probability of an end of study Go is: 0.1478</li>
<li>The probability of an end of study No-Go (Stop) is: 0.2656</li>
<li>The probability of futility at the interim: 0.5866</li>
<li>The probability of a Go conditional on not stopping at the interim:
0.357523</li>
<li>The probability of a No-Go conditional on not stopping at the
interim: 0.642477</li>
</ul>
<p>The posterior mean of the true delta,
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>Œº</mi><mi>E</mi></msub><mo>‚àí</mo><msub><mi>Œº</mi><mi>S</mi></msub></mrow><annotation encoding="application/x-tex">\mu_E-\mu_S</annotation></semantics></math>,
given a Go decision is: 0.992</p>
<p>The summary of the true delta given a Go decision is:</p>
<pre><code><span><span class="co">##    Min. 1st Qu.  Median    Mean 3rd Qu.    Max. </span></span>
<span><span class="co">##   0.023   0.823   0.990   0.992   1.151   2.009</span></span></code></pre>
<p>The scaled posterior distribution of the true delta given a Go
decision is:</p>
<p><img src="AssuranceConsecutiveStudies_files/figure-html/unnamed-chunk-10-1.png" width="700"></p>
</div>
</div>
<div class="section level2">
<h2 id="example-3">Example 3<a class="anchor" aria-label="anchor" href="#example-3"></a>
</h2>
<div class="section level3">
<h3 id="study-design-1">Study Design<a class="anchor" aria-label="anchor" href="#study-design-1"></a>
</h3>
<p>This study is a two-arm fixed sample size design with a time-to-event
endpoint. Total sample size is 600 patients with 300 patients per arm.
There is a single analysis when 50% of the patients have had their event
observed. A hazard ratio (HR) below 1 is considered to favor the
experimental arm. The analysis is assumed to be a cox proportional
hazard model where a Go decision is made if the p-value
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mo>‚â§</mo><annotation encoding="application/x-tex">\leq</annotation></semantics></math>
0.025.</p>
<p>For assurance, a bi-modal prior on the Log(HR) is used. The
components of the prior are:</p>
<ul>
<li>Weight: 25% on
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>N</mi><mrow><mo stretchy="true" form="prefix">(</mo><mn>0</mn><mo>,</mo><mn>0.02</mn><mo stretchy="true" form="postfix">)</mo></mrow></mrow><annotation encoding="application/x-tex">N( 0, 0.02 )</annotation></semantics></math>
</li>
<li>Weight: 75% on
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi><mi>e</mi><mi>t</mi><mi>a</mi><mrow><mo stretchy="true" form="prefix">(</mo><mn>2</mn><mo>,</mo><mn>2</mn><mo stretchy="true" form="postfix">)</mo></mrow></mrow><annotation encoding="application/x-tex">Beta( 2, 2)</annotation></semantics></math>,
rescaled between -0.4 and 0.</li>
</ul>
<p><img src="AssuranceConsecutiveStudies_files/figure-html/unnamed-chunk-11-1.png" width="700"></p>
</div>
<div class="section level3">
<h3 id="r-integration-1">R Integration<a class="anchor" aria-label="anchor" href="#r-integration-1"></a>
</h3>
<div class="section level4">
<h4 id="required-r-functions-1">Required R Functions<a class="anchor" aria-label="anchor" href="#required-r-functions-1"></a>
</h4>
<p>This are 3 required R files and functions needed to evaluate this
design. The first file is used to initialize the R environment and load
the survival package. The second file is used to perform the analysis
using a Cox model. The third required file is used to first simulate the
true HR from the prior and then simulate the patient data using the
sampled HR.</p>
<p>The initialize function InitializeSurvival is found in the file <a href="https://github.com/Cytel-Inc/CyneRgy/blob/main/inst/Examples/AssuranceConsecutiveStudies/R/InitializeSurvival.R" class="external-link">R/SimulatePatientOutcomeNormalAssurance.R</a>.
The function used for analysis is AnalyzeSurivalDataUsingCoxPH, is found
in the file <a href="https://github.com/Cytel-Inc/CyneRgy/blob/main/inst/Examples/AssuranceConsecutiveStudies/R/AnalyzeSurvivalDataUsingCoxPH.R" class="external-link">R/AnalyzeSurvivalDataUsingCoxPH.R</a>
The function used for simulating patient data is
SimulatePatientOutcomeNormalAssurance and is found in the file <a href="https://github.com/Cytel-Inc/CyneRgy/blob/main/inst/Examples/AssuranceConsecutiveStudies/R/SimulatePatientOutcomeNormalAssurance.R" class="external-link">R/SimulatePatientOutcomeNormalAssurance.R</a></p>
</div>
<div class="section level4">
<h4 id="integration-with-east">Integration with East<a class="anchor" aria-label="anchor" href="#integration-with-east"></a>
</h4>
<p>The required user input for generating patient survival in East is
provided below.</p>
<div class="float">
<img src="Example3GenerateResponseInput.jpg" alt="Input for generate response"><div class="figcaption">Input for generate response</div>
</div>
</div>
<div class="section level4">
<h4 id="integration-with-east-horizon-explore">Integration with East Horizon Explore<a class="anchor" aria-label="anchor" href="#integration-with-east-horizon-explore"></a>
</h4>
<p>The required user input for generating patient survival in East
Horizon Explore is provided below.</p>
<div class="float">
<img src="Example3GenerateResponseSolara.jpg" alt="Input for generate response"><div class="figcaption">Input for generate response</div>
</div>
</div>
</div>
<div class="section level3">
<h3 id="results-2">Results<a class="anchor" aria-label="anchor" href="#results-2"></a>
</h3>
<p>The probability of a Go decision is 33% and the probability of a
No-Go Decision is is 67%. The posterior distribution of the true Log( HR
) given a Go decision is:</p>
<p><img src="AssuranceConsecutiveStudies_files/figure-html/unnamed-chunk-13-1.png" width="700"><img src="AssuranceConsecutiveStudies_files/figure-html/unnamed-chunk-13-2.png" width="700"></p>
</div>
</div>
<div class="section level2">
<h2 id="example-4---two-consecutive-studies-and-de-risking">Example 4 - Two Consecutive Studies and De-risking<a class="anchor" aria-label="anchor" href="#example-4---two-consecutive-studies-and-de-risking"></a>
</h2>
<p>In this section we explore computing assurance and conditional
assurance for two consecutive studies. A phase 2 with normal endpoints
(similar setup to Example 1) followed by a Phase 3 with a normal
endpoint.</p>
<p>The goal is to understand how much the phase 3 trial can be de-risked
by first running a phase 2 study to gather additional information.
De-risking is determined by comparing the probability of a No-Go in a
phase 3 if the phase 2 was skipped versus the probability of a No-Go in
phase 3 if the phase 2 was first conducted and successful. Specifically,
we compute the assurance of the phase 3 conditional on a Go decision in
phase 2.</p>
<div class="section level3">
<h3 id="study-design---phase-2">Study Design - Phase 2<a class="anchor" aria-label="anchor" href="#study-design---phase-2"></a>
</h3>
<p>Same priors as Example 1.</p>
<p>Fixed sample, with normally distributed outcomes Y.</p>
<ul>
<li>Sample size: 80 patients per arm</li>
<li>Assume standard deviation is known:
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>œÉ</mi><mo>=</mo><mn>1.9</mn></mrow><annotation encoding="application/x-tex">\sigma = 1.9</annotation></semantics></math>
</li>
<li>MAV = 0.6</li>
<li><math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>P</mi><mi>U</mi></msub><mo>=</mo><mn>0.8</mn></mrow><annotation encoding="application/x-tex">P_U = 0.8</annotation></semantics></math></li>
</ul>
<div class="section level4">
<h4 id="results-for-phase-2">Results For Phase 2<a class="anchor" aria-label="anchor" href="#results-for-phase-2"></a>
</h4>
<p>The probability of a Go is 26.7% and the probability of a No-Go is
73.3%.</p>
<p><img src="AssuranceConsecutiveStudies_files/figure-html/unnamed-chunk-15-1.png" width="700"></p>
</div>
</div>
<div class="section level3">
<h3 id="study-design---phase-3">Study Design - Phase 3<a class="anchor" aria-label="anchor" href="#study-design---phase-3"></a>
</h3>
<p>Fixed sample, with normally distributed outcomes Y.</p>
<ul>
<li>Sample size: 200 patients per arm</li>
<li>Assume standard deviation is known:
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>œÉ</mi><mo>=</mo><mn>1.9</mn></mrow><annotation encoding="application/x-tex">\sigma = 1.9</annotation></semantics></math>
</li>
<li>MAV = 0.6</li>
<li><math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>P</mi><mi>U</mi></msub><mo>=</mo><mn>0.5</mn></mrow><annotation encoding="application/x-tex">P_U = 0.5</annotation></semantics></math></li>
</ul>
<p>With MAV = 0.6 and
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>P</mi><mi>U</mi></msub><mo>=</mo><mn>0.5</mn></mrow><annotation encoding="application/x-tex">P_U = 0.5</annotation></semantics></math>
this design is equivalent to using a t-test because the critical value
would be 0.6 and having a posterior probability greater than 0.5 would
indicate that the estimated treatment difference is above the critical
value.</p>
<div class="section level4">
<h4 id="results-for-phase-3">Results For Phase 3<a class="anchor" aria-label="anchor" href="#results-for-phase-3"></a>
</h4>
<p>The probability of a Go in Phase 3 is 46% and the probability of a
No-Go is 54%.</p>
<p><img src="AssuranceConsecutiveStudies_files/figure-html/unnamed-chunk-17-1.png" width="700"></p>
</div>
</div>
<div class="section level3">
<h3 id="phase-2-followed-by-phase-3">Phase 2 followed by Phase 3<a class="anchor" aria-label="anchor" href="#phase-2-followed-by-phase-3"></a>
</h3>
<p>Using a Phase 2 design like above.</p>
<p><em>Phase 2</em></p>
<p>Fixed sample, with normally distributed outcomes Y.</p>
<ul>
<li>Sample size: 80 patients per arm</li>
<li>Assume standard deviation is known:
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>œÉ</mi><mo>=</mo><mn>1.9</mn></mrow><annotation encoding="application/x-tex">\sigma = 1.9</annotation></semantics></math>
</li>
<li>MAV = 0.6</li>
<li><math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>P</mi><mi>U</mi></msub><mo>=</mo><mn>0.8</mn></mrow><annotation encoding="application/x-tex">P_U = 0.8</annotation></semantics></math></li>
</ul>
<p>If the Phase 2 makes a Go decision then the Phase 3 is conducted as
follows:</p>
<p>Fixed sample, with normally distributed outcomes Y.</p>
<ul>
<li>Sample size: 200 patients per arm</li>
<li>Assume standard deviation is known:
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>œÉ</mi><mo>=</mo><mn>1.9</mn></mrow><annotation encoding="application/x-tex">\sigma = 1.9</annotation></semantics></math>
</li>
<li>MAV = 0.6</li>
<li><math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>P</mi><mi>U</mi></msub><mo>=</mo><mn>0.5</mn></mrow><annotation encoding="application/x-tex">P_U = 0.5</annotation></semantics></math></li>
</ul>
<div class="section level4">
<h4 id="results-for-phase-2-followed-by-phase-3">Results For Phase 2 Followed by Phase 3<a class="anchor" aria-label="anchor" href="#results-for-phase-2-followed-by-phase-3"></a>
</h4>
<p>Given a Go decision is made in Phase 2, the probability of a Go in
Phase 3 is 84.8% and the probability of a No-Go is 15.2%.</p>
<p><img src="AssuranceConsecutiveStudies_files/figure-html/unnamed-chunk-19-1.png" width="700"></p>
</div>
<div class="section level4">
<h4 id="de-risking">De-risking<a class="anchor" aria-label="anchor" href="#de-risking"></a>
</h4>
<p>Comparing the option of running only a Phase 3 versus a Phase 2
followed by a Phase 3 if Phase 2 is successful, the probability of Go in
phase 3 increases from 46% to 84.8% and the probability of a No-Go in
Phase 3 decreases from 54% to 15.2%.</p>
</div>
</div>
</div>
<div class="section level2">
<h2 id="example-5---two-consecutive-studies-and-de-risking">Example 5 - Two Consecutive Studies and De-risking<a class="anchor" aria-label="anchor" href="#example-5---two-consecutive-studies-and-de-risking"></a>
</h2>
<p>In this section we explore computing assurance and conditional
assurance for two consecutive studies. A phase 2 with normal endpoints
(similar setup to Example 1) followed by a Phase 3 with a time-to-event
endpoint.</p>
<div class="section level3">
<h3 id="study-design-phase-2">Study Design Phase 2<a class="anchor" aria-label="anchor" href="#study-design-phase-2"></a>
</h3>
<p>Same priors as Example 1.</p>
<p>Fixed sample, with normally distributed outcomes Y.</p>
<ul>
<li>Sample size: 80 patients per arm</li>
<li>Assume standard deviation is known:
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>œÉ</mi><mo>=</mo><mn>1.9</mn></mrow><annotation encoding="application/x-tex">\sigma = 1.9</annotation></semantics></math>
</li>
<li>MAV = 0.6</li>
<li><math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>P</mi><mi>U</mi></msub><mo>=</mo><mn>0.8</mn></mrow><annotation encoding="application/x-tex">P_U = 0.8</annotation></semantics></math></li>
</ul>
<div class="section level4">
<h4 id="results-for-phase-2-1">Results For Phase 2<a class="anchor" aria-label="anchor" href="#results-for-phase-2-1"></a>
</h4>
<p>The probability of a Go is 26.7% and the probability of a No-Go is
73.3%.</p>
<p><img src="AssuranceConsecutiveStudies_files/figure-html/unnamed-chunk-21-1.png" width="700"></p>
</div>
</div>
<div class="section level3">
<h3 id="study-design-phase-3">Study Design Phase 3<a class="anchor" aria-label="anchor" href="#study-design-phase-3"></a>
</h3>
<p>This study is a two-arm fixed sample size design with a time-to-event
endpoint. Total sample size is 600 patients with 300 patients per arm.
There is a single analysis when 50% of the patients have had their event
observed. A hazard ratio (HR) below 1 is considered to favor the
experimental arm. The analysis is assumed to be a cox proportional
hazard model where a Go decision is made if the p-value
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mo>‚â§</mo><annotation encoding="application/x-tex">\leq</annotation></semantics></math>
0.025.</p>
<p>The relationship between the continuous endpoint in phase 2 and the
time-to-event endpoint in phase 3 is assumed to follow a linear
function:</p>
<p><math display="block" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>l</mi><mi>o</mi><mi>g</mi><mrow><mo stretchy="true" form="prefix">(</mo><mspace width="0.222em"></mspace><mi>T</mi><mi>r</mi><mi>u</mi><mi>e</mi><mspace width="0.222em"></mspace><mi>H</mi><mi>R</mi><mspace width="0.222em"></mspace><mo stretchy="true" form="postfix">)</mo></mrow><mrow><mspace width="0.333em"></mspace><mtext mathvariant="normal"> in phase 3 = 0.1 ‚àí 0.4 ‚àó ( true treatment difference in phase 2)</mtext></mrow></mrow><annotation encoding="application/x-tex"> 
log(\ True \ HR\ ) \text{ in phase 3 = 0.1 ‚àí 0.4 ‚àó ( true treatment difference in phase  2)}
</annotation></semantics></math></p>
<p>Note that the relationship is established on the true treatment
effects. Since the phase 2 provides a prior on the true treatment
different and we have the linear link function between the true
treatment difference and the true HR, we do not need to specify the
prior on the true HR like in Example 3.</p>
</div>
<div class="section level3">
<h3 id="east-r-integration">East-R Integration<a class="anchor" aria-label="anchor" href="#east-r-integration"></a>
</h3>
<p>For this example, in the East workbook Example 5 - Phase 2 is used to
simulate the phase 2 and Example 5 - Phase 3 is used to simulate the
phase 3 for both the conditional and unconditional assurance
calculations. When the phase 2 is simulated, the true treatment
different is sampled from the prior is saved in the output file from
phase 2. Both the conditional and unconditional phase 3 use an R
initialize function to read in the output from the phase 2 and obtain
the true treatment difference which is then converted to the log of the
true HR given the link function above. Note, for the unconditional
assurance an alternative approach would be to sample the phase 2 prior
directly rather then read the output from phase 2. However, reading the
true values in from the phase 2 creates a more consistent comparison
between the conditional and unconditional assurance calculations and a
more accurate estimate of the benefit of running the phase 2 prior to
the phase 3.</p>
<div class="section level4">
<h4 id="required-r-function">Required R Function<a class="anchor" aria-label="anchor" href="#required-r-function"></a>
</h4>
<p>For the phase 2, the same functions are needed as Example 2.</p>
<p>The two functions that are needed to evaluate this design and obtain
the Bayesian assurance are the analysis function,
AnayzeUsingBayesianNormals, and patient simulation function,
SimulatePatientOutcomeNormalAssurance.</p>
<p>For the phase 3, three functions are needed: 1)
ReadExample5Phase2Output, 2) AnalyzeSurvivalDataUsingCoxPh, and 3)
SimulatePatientSurvivalAssuranceUsingPh2Pior and the functions are
located in the R directory in the file with the matching file name. The
ReadExample5Phase2Output is called from the Initialize R Environment in
East and loads the survival package as it is needed for the coxph
function and also reads in the true treatment difference from phase 2.
Note the use of the &lt;&lt;- operator to create a global variables
vPrior, the vector with the treatment difference, and nSimIndex to keep
track of which simulation index or replication the simulation is
executing when the call to SimulatePatientSurvivalAssuranceUsingPh2Pior
is executed. Both vPrior and nSimIndex are utilized in the function
SimulatePatientSurvivalAssuranceUsingPh2Pior and the nSimIndex variable
is updated with each call.</p>
<p>The function ReadExample5Phase2Output utilizes the UserParam
variables from East and if UserParam$bConditionalOnGo is 1, then only
the true treatment effects that resulted in a Go decision in Phase 2 are
retained allowing the simulation to compute the conditional assurance.
Note that the number of replications used in simulating the phase 3 for
conditional assurance must be less than or equal to the number of
simulated phase 2 trials that were successful. If
UserParam$bConditionalOnGo is 0 then all true treatment effects sampled
in the Phase 2 are retained allowing the simulation to compute the
unconditional assurance.</p>
</div>
</div>
<div class="section level3">
<h3 id="results-phase-3-no-phase-2-conducted">Results Phase 3, No Phase 2 Conducted<a class="anchor" aria-label="anchor" href="#results-phase-3-no-phase-2-conducted"></a>
</h3>
<p>For Phase 3, the unconditional probability of a Go decision is 29%
and the unconditional probability of a No-Go Decision is 71%. The 95%
posterior credible for the Log( True HR ) is
(-<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mi>‚àû</mi><annotation encoding="application/x-tex">\infty</annotation></semantics></math>,
0.12 ). The posterior distribution of the true Log( HR ) given a Go
decision is:</p>
<p><img src="AssuranceConsecutiveStudies_files/figure-html/unnamed-chunk-23-1.png" width="700"></p>
</div>
<div class="section level3">
<h3 id="results-phase-3-conditional-on-phase-2-go-decision">Results Phase 3, Conditional on Phase 2 Go Decision<a class="anchor" aria-label="anchor" href="#results-phase-3-conditional-on-phase-2-go-decision"></a>
</h3>
<p>For Phase 3, conditional on the phase 2 making a go decision, the
probability of a Go decision is 60% and the unconditional probability of
a No-Go Decision is 40%. The 95% posterior credible for the Log( True HR
) is (-0.46, -0.08). The posterior distribution of the true Log( HR )
given a Phase 3 Go decision is:</p>
<p><img src="AssuranceConsecutiveStudies_files/figure-html/unnamed-chunk-25-1.png" width="700"></p>
<div class="section level4">
<h4 id="de-risking-1">De-risking<a class="anchor" aria-label="anchor" href="#de-risking-1"></a>
</h4>
<p>Comparing the option of running only a Phase 3 versus a Phase 2
followed by a Phase 3 if Phase 2 is successful, the probability of Go in
phase 3 increases from 29% to 60% and the probability of a No-Go in
Phase 3 decreases from 71% to 40%.</p>
</div>
</div>
</div>
  </main><aside class="col-md-3"><nav id="toc" aria-label="Table of contents"><h2>On this page</h2>
    </nav></aside>
</div>



    <footer><div class="pkgdown-footer-left">
  <p>Developed by J. Kyle Wathen, Valeria A. G. Mazzanti.</p>
</div>

<div class="pkgdown-footer-right">
  <p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.1.1.</p>
</div>

    </footer>
</div>





  </body>
</html>
